Search

Your search keyword '"Orens, Jonathan B."' showing total 213 results
Start Over Author "Orens, Jonathan B." Language english
213 results on '"Orens, Jonathan B."'

1. Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease

Author

Keller, Michael B., Newman, David, Alnababteh, Muhtadi, Ponor, Lucia, Shah, Pali, Mathew, Joby, Kong, Hyesik, Andargie, Temesgen, Park, Woojin, Charya, Ananth, Luikart, Helen, Aryal, Shambhu, Nathan, Steven D., Orens, Jonathan B., Khush, Kiran K., Jang, Moon, and Agbor-Enoh, Sean

Published
2024
Full Text
View/download PDF

3. Development and validation of primary graft dysfunction predictive algorithm for lung transplant candidates

Author

Diamond, Joshua M., Anderson, Michaela R., Cantu, Edward, Clausen, Emily S., Shashaty, Michael G.S., Kalman, Laurel, Oyster, Michelle, Crespo, Maria M., Bermudez, Christian A., Benvenuto, Luke, Palmer, Scott M., Snyder, Laurie D., Hartwig, Matthew G., Wille, Keith, Hage, Chadi, McDyer, John F., Merlo, Christian A., Shah, Pali D., Orens, Jonathan B., Dhillon, Ghundeep S., Lama, Vibha N., Patel, Mrunal G., Singer, Jonathan P., Hachem, Ramsey R., Michelson, Andrew P., Hsu, Jesse, Russell Localio, A., and Christie, Jason D.

Published
2024
Full Text
View/download PDF

5. Higher Molecular Injury at Diagnosis of Acute Cellular Rejection Increases the Risk of Lung Allograft Failure: A Clinical Trial.

Author

Keller, Michael B., Tian, Xin, Jang, Moon Kyoo, Meda, Rohan, Charya, Ananth, Berry, Gerald J., Marboe, Charles C., Kong, Hyesik, Ponor, Ileana L., Aryal, Shambhu, Orens, Jonathan B., Shah, Pali D., Nathan, Steven D., and Agbor-Enoh, Sean

Subjects
GRAFT rejection, HOMOGRAFTS, MOLECULAR diagnosis, LUNG transplantation, CLINICAL trials, KIDNEY failure
Abstract

Rationale: The association of acute cellular rejection (ACR) with chronic lung allograft dysfunction (CLAD) in lung transplant recipients has primarily been described before consensus recommendations incorporating restrictive phenotypes. Furthermore, the association of the degree of molecular allograft injury during ACR with CLAD or death remains undefined. Objectives: To investigate the association of ACR with the risk of CLAD or death and to further investigate if this risk depends on the degree of molecular allograft injury. Methods: This multicenter, prospective cohort study included 188 lung transplant recipients. Subjects underwent serial plasma collections for donor-derived cell-free DNA (dd-cfDNA) at prespecified time points and bronchoscopy. Multivariable Cox proportional-hazards analysis was conducted to analyze the association of ACR with subsequent CLAD or death as well as the association of dd-cfDNA during ACR with risk of CLAD or death. Additional outcomes analyses were performed with episodes of ACR categorized as "high risk" (dd-cfDNA ⩾ 1%) and "low risk" (dd-cfDNA < 1%). Measurements and Main Results: In multivariable analysis, ACR was associated with the composite outcome of CLAD or death (hazard ratio [HR], 2.07 [95% confidence interval (CI), 1.05–4.10]; P = 0.036). Elevated dd-cfDNA ⩾ 1% at ACR diagnosis was independently associated with increased risk of CLAD or death (HR, 3.32; 95% CI, 1.31–8.40; P = 0.012). Patients with high-risk ACR were at increased risk of CLAD or death (HR, 3.13; 95% CI, 1.41–6.93; P = 0.005), whereas patients with low–risk status ACR were not. Conclusions: Patients with ACR are at higher risk of CLAD or death, but this may depend on the degree of underlying allograft injury at the molecular level. Clinical trial registered with (NCT 02423070). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension

Author

Porteous, Mary K., Lee, James C., Lederer, David J., Palmer, Scott M., Cantu, Edward, Shah, Rupal J., Bellamy, Scarlett L., Lama, Vibha N., Bhorade, Sangeeta M., Crespo, Maria M., McDyer, John F., Wille, Keith M., Localio, Russell A., Orens, Jonathan B., Shah, Pali D., Weinacker, Ann B., Arcasoy, Selim, Wilkes, David S., Ware, Lorraine B., Christie, Jason D., Kawut, Steven M., and Diamond, Joshua M.

Published
2017
Full Text
View/download PDF

43. Acute effects of bilateral lung volume reduction surgery on lung and chest wall properties

Author

Barnas, George M., Gilbert, Timothy B., Krasna, Mark J., McGinley, Mark J., Fiocco, Michael, and Orens, Jonathan B.

Subjects
Lungs -- Surgery, Emphysema, Pulmonary -- Physiological aspects -- Measurement, Respiration -- Measurement -- Physiological aspects, Surgery -- Physiological aspects -- Measurement, Health, Physiological aspects, Measurement
Abstract

Study objectives: To characterize acute changes in the dynamic, passive mechanical properties of the lungs and chest wall, elastance (E) and resistance (R), caused by lung volume reduction surgery (LVRS). [...]

Published
1998

47. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation

Author

Martinez, Fernando J., Orens, Jonathan B., Deeb, Michael, Brunsting, Louis A., Flint, Andrew, and Lynch, III, Joseph P.

Subjects
Lungs -- Transplantation, Sarcoidosis -- Case studies, Health, Case studies
Abstract

We report the first case of recurrent sarcoidosis manifested by clinical symptoms, radiographic abnormalities, and pathologic changes in a patient following sequential double allogeneic lung transplantation. A 40-year-old male patient [...]

Published
1994

48. Prevention of Airway Allograft Tolerance by Poly (I:C) Requires Type-I Interferon Responsiveness for Mouse Airway Obliteration

Author

Miller, Hannah L., Shah, Pali D., Orens, Jonathan B., and McDyer, John F.

Subjects
Graft Rejection, Mice, Knockout, Mice, Inbred BALB C, Interferon Inducers, CD40 Ligand, Antibodies, Monoclonal, CD8-Positive T-Lymphocytes, Allografts, Article, Mice, Inbred C57BL, Trachea, Disease Models, Animal, Mice, Phenotype, Poly I-C, Treatment Outcome, Interferon Type I, Animals, Female, Bronchiolitis Obliterans, Cell Proliferation, RNA, Double-Stranded
Abstract

Respiratory RNA viruses are associated with bronchiolitis obliterans syndrome (BOS) in lung transplant recipients (LTRS); however, the immune mechanisms that regulate airway obliteration remain incompletely understood.Using the mouse heterotopic tracheal transplant model of obliterative airway disease (OAD), we studied the role of double-stranded (ds)RNA using polyinosinic:polycytidylic acid (poly[I:C]), a synthetic analog of viral dsRNA, in abrogating airway allograft tolerance established with donor-specific transfusion (DST) and anti-CD154 monoclonal antibody therapy.Wild-type (WT) B6 recipients of accepted BALB/c airway grafts demonstrated significantly reduced intragraft CD8+ T cells, with markedly impaired allospecific interferon (INF)-γ and tumor necrosis factor-α secretion, uncoupled from an activated phenotype, and evidence of proliferation. Administration of poly(I:C) to DST/anti-CD154-treated recipients restored OAD pathology and CD8+ alloeffector responses to levels observed in untreated mice. However, B6 type I IFN receptor-deficient (IFN-αβR(-/-)) recipients were resistant to the abrogation of tolerance mediated by poly(I:C) and did not develop CD8+ alloeffector responses or OAD. Further, adoptive transfers of WT CD8+ T cells or CD11c+ dendritic cells alone into B6 IFNαβR(-/-) recipients treated with poly(I:C) and DST/anti-CD154 were incapable of abrogating airway graft tolerance.Together, these data indicate abrogation of DST/anti-CD154-induced airway allograft tolerance via dsRNA requires type-I IFN responsiveness for mouse airway obliteration.

Published
2013

49. Selection of Candidates for Lung Transplantation and Controversial Issues.

Author

Orens, Jonathan B. and Merlo, Christian A.

Subjects
*LUNG transplantation, *LUNG disease treatment, *QUALITY of life, *COMORBIDITY, *LIFE expectancy, *AGE distribution, *LUNG diseases, *MEDICAL protocols, *PATIENT selection, *FERRANS & Powers Quality of Life Index
Abstract

Lung transplantation is a widely accepted treatment to manage the advanced stages of many lung diseases that have failed to respond to all other therapeutic interventions. There have been ever-expanding indications for lung transplantation as a treatment for lung disease. The International Society for Heart and Lung Transplantation (ISHLT) updated guidelines for candidate selection in 2014. This document was published to serve as a guide in selecting appropriate candidates for lung transplantation. Ideal candidates for lung transplantation are those with near-end stage disease, limited life expectancy due to their lung disease, and who experience significant loss in quality of life. At the same time, candidates should be free of significant comorbidities that might negatively impact successful transplantation. Despite well thought out published guidelines for candidate selection, many controversial issues surrounding selection of lung transplant candidates remain. This review will focus on some of the more common controversial issues and explain how most centers approach these issues when choosing candidates for lung transplantation. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Severe Acute Kidney Injury According to the RIFLE Criteria Affects Mortality in Lung Transplantation

Author

Arnaoutakis, George J., George, Timothy J., Robinson, Chase W., Gibbs, Kevin W., Orens, Jonathan B., Merlo, Christian A., and Shah, Ashish S.

Subjects
Adult, Lung Diseases, Male, Comorbidity, Kaplan-Meier Estimate, Acute Kidney Injury, Length of Stay, Middle Aged, Hospital Charges, Risk Assessment, Severity of Illness Index, Article, Creatinine, Baltimore, Multivariate Analysis, Linear Models, Humans, Female, Hospital Mortality, Glomerular Filtration Rate, Lung Transplantation, Retrospective Studies
Abstract

The RIFLE criteria (risk, injury, failure, loss, end stage) are new consensus definitions for acute kidney injury (AKI) associated with increased mortality; however, they have not been applied in lung transplantation (LTx). Using the RIFLE criteria, we examined the effect of AKI on outcomes and cost in LTx.We retrospectively reviewed all LTx patients at our institution since the lung allocation score (LAS) system was initiated (May 2005-August 2010). Using the Modification of Diet in Renal Disease formula, we assigned appropriate RIFLE class (R, I, F) comparing baseline creatinine to peak levels in the first 7 days after LTx. Generalized linear models assessed the effect of AKI on in-hospital and 1-year mortality. Hospital charges were used to examine the financial effect of AKI.During the study, 106 LTx were performed. Excluding patients bridged to LTx with extracorporeal membrane oxygenation, 84 (86%) lived 1 year. Median LAS was 37.1 (interquartile range, 34.1-45.2). RIFLE status was I or F in 39 (36.7%), and 14 (13.2%) required renal replacement therapy (RRT). After adjusting for LAS, RIFLE-F had an increased relative rate (RR) of in-hospital mortality (RR, 4.76, 95% confidence interval [CI], 1.65-13.7, p = 0.004) and 1-year mortality (RR, 3.17, 95% CI 1.55-6.49, p = 0.002). RIFLE-R and I were not associated with higher in-hospital or 1-year mortality. Post-operative RRT was associated with increased in-hospital (RR, 28.2; 95% CI, 6.18-128.1; p0.001) and 1-year mortality (RR, 4.97; 95% CI, 1.54-16.0; p0.001). AKI patients had higher median hospital charges of $168,146 vs $143,551 for no AKI (p = 0.02).This study shows high rates of AKI using the new RIFLE criteria in LTx. RIFLE-F is associated with higher in-hospital and 1-year mortality. Less severe degrees of AKI are not associated with increased mortality. The financial burden associated with AKI is significant.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results